Michael Chancellor, Chief Medical Officer of Lipella Pharmaceuticals, commented, "The allowance of this patent is a significant milestone for Lipella as it strengthens our intellectual property ...
This one-year full-time or two-year part-time master's programme gives you an understanding of applied clinical sciences, research methods and the concepts of oral and maxillofacial surgery. You will ...
While some may need to be removed, many don’t require any treatment at all. Benign oral cavity tumors are essentially noncancerous lesions in the mouth. This means that they do not metastasize ...
Pharmaceutical Technology Europe sat down with Uwe Hanenberg, Head of Product Implementation at Recipharm, to talk about key trends shaping the oral solid dosage market, including technology advances ...